Friday, March 01, 2019—After 24 weeks of treatment, patients treated with 75 mg of evobrutinib (EMD Serono, Rockland, MA) 2 or 4 times per day had significantly fewer T1 gadolinium-enhancing (Gd+) l…
Monday, February 25, 2019—The Food and Drug Administration (FDA) has accepted an application for diroximel fumarate (BIIB098; Alkermes, Waltham, MA and Biogen, Cambridge, MA) for the treatment of relap…
Tuesday, February 19, 2019—A study published in the journal Neurology suggests prevalence of multiple sclerosis (MS) in the US is 913,925 -- more than twice the previous estimate of 400,000 pe…
Alexandra Galati, MD; and Marwa Kaisey, MD
February 2019—Accurate diagnosis requires correspondence to typical clinical syndromes, correct interpretation of radiologic and CSF data, and thorough evaluation for mimics.
David B. Clifford, MD; and John F. Foley, MD
February 2019—Optimism vs caution for using extended-interval dosing to prevent progressive multifocal leukoencephalopathy.
Matthew Tremblay, MD, PhD
February 2019—A number of agents with putative neuroprotective effects have shown promise in recent clinical trials.
Michelle H. Cameron, MD, PhD, MCR; and Ylva E. Nilsagård, PT, PhD
February 2019—Physical therapy, exercise, physical activity, and medications adapted to individual needs can all help maintain the ability to walk.
Ye Hu, MD; Neeta Garg, MD; and Kottil W. Rammohan, MD
February 2019—Disruption of immune tolerance, inflammation, and blood-brain–barrier breach lead to demyelination and axonal injury.